Eli Lilly & Co.’s antibody therapy was granted an emergency-use authorization by U.S. drug regulators for treating Covid-19, widening access to a treatment that early data suggests is effective in keeping people infected with the coronavirus out of the hospital.

The Food and Drug Administration authorized the treatment, called bamlanivimab, for use against mild-to-moderate Covid-19 in adult and pediatric patients, the agency said on its website.

Shares of Eli Lilly gained 4.5% in late trading on Monday. Through the close, the stock had advanced 8.3% so far this year.

Read More →